MAY 26, 2015 09:00 AM PDT

Intelligent NGS Assay Design: Oncomine™ Focus Assay for NGS clinical research in oncology

  • Director of Oncology, Research & Development, Thermo Fisher Scientific
      Seth Sadis is the Director of Oncology, Research & Development in the Genetic, Applied, and Medical Sciences Division of Thermo Fisher Scientific.

      Currently Dr . Sadis leads a team of Software Engineers, Bioinformaticists and Translational Oncology scientists to develop both research assays and diagnostic tests on the Ion TorrentÔ next generation sequencing platform, capillary electrophoresis sequencing systems, as well as qPCR and digital PCR platforms.

      Dr. Sadis earned a Ph.D in Biochemistry and completed a postdoctoral fellowship at Harvard Medical School. His professional career includes 15 years in biopharma industry, spanning oncology drug discovery through clinical development and diagnostics.

    DATE: Tuesday, May 26th, 2015
    TIME: 09:00AM PDT, 12:00PM EDT

    Next-generation sequencing (NGS) is changing the landscape of clinical research. This powerful technology is enabling researchers to move from running many sequential tests to a single workflow that provides DNA and RNA results across many genes with the detection of relevant SNPs, CNVs, gene fusions and indels.

    Learn how our NGS experts are impacting research today and gain valuable insights into their assay design process.

    We will cover the following:
    - Overview of Oncomine™ Assay products
    - Oncomine™ Assay design approach
    - Performance and results

    Show Resources
    Loading Comments...